After a recent shortage of Shire's rare disease drug, Cinryze, they are looking to bring some manufacturing in house. This comes on the heels of Shire announcing the closer of three more plants.
Shire has already asked the FDA for permission to manufacture Cinryze at one of the plants it received in its Baxalta buyout last year and is hopeful that production can begin in the first quarter of 2018.
These will not be the last plants to close or be sold as Shire continues to balance out manufacturing and cut costs.
Click here to view the entire article.